Prosecution Insights
Prosecution Insights
Tech Center 1700 • Art Units: 1651 1657 1677 1692 1798
This examiner grants 70% of resolved cases
Leon B Lankford Jr works in Tech Center 1700 and Art Unit 1651 with 751 resolved cases. His allowance rate pct is 70.0, and the median days to allowance is 1353. These figures indicate the path to allowance for applicants. The 1353-day median to allowance is a benchmark for applicants navigating Art Unit 1651 and managing their patent portfolios.
The interview lift pct of 31.6 is a metric suggesting that interviews are a component of a successful strategy. This 31.6 lift indicates that verbal advocacy can increase the 70.0 allowance rate pct. The 751 resolved cases provide a statistical foundation for these observations. A 31.6 lift is a signal that direct communication is an effective way to move an application toward a grant with this examiner and potentially address the 1353-day median pendency.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18037646 | TISSUE ORGANOID BIOPRINTING AND HIGH-THROUGHPUT SCREENING METHODOLOGY | Non-Final OA | The Regents of the University of California |
| 18284108 | METHODS FOR PREPARING L-GLUFOSINATE | Non-Final OA | BASF SE |
| 18558133 | IL6 MARKER PANELS FOR EARLY DETECTION OF SEPSIS | Non-Final OA | Roche Diagnostics Operations, Inc. |
| 18558150 | ESM1 MARKER PANELS FOR EARLY DETECTION OF SEPSIS | Non-Final OA | Roche Diagnostics Operations, Inc. |
| 18284239 | COMPOSITION FOR ENHANCING PHYSIOLOGICAL EFFICACY OF LACTIC ACID BACTERIA | Final Rejection | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION |
| 18294648 | NOVEL FLAVIN-DEPENDENT LACTATE DEHYDROGENASE AND METHOD FOR IMPROVING STABILITY OF LACTATE DEHYDROGENASE | Non-Final OA | KIKKOMAN CORPORATION |
| 18852803 | METHODS OF DIAGNOSING IBS-D AND SELECTION OF IBS-D TREATMENT | Non-Final OA | Cedars-Sinai Medical Center |
| 18867802 | Enzymes and Uses in Biocatalytic Halogenation of N-Heteroaryls Thereof | Non-Final OA | Agency for Science, Technology and Research |
| 18863111 | Methods for Treating Pompe Disease | Non-Final OA | Amicus Therapeutics, Inc. |
| 18662758 | RPE CELL POPULATIONS AND METHODS OF GENERATING SAME | Non-Final OA | CELL CURE NEUROSCIENCES LTD. |
| 18330510 | CORNEAL ENDOTHELIUM ECM THERAPEUTIC MEDICAMENTS | Non-Final OA | SENJU PHARMACEUTICAL CO., LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy